Search / Trial NCT06786871

ARTLifeLine: Assisted Reproduction Technology (ART) Family Health and Development Trajectory Cohort (ARTLL)
Launched by PEKING UNIVERSITY THIRD HOSPITAL · Jan 19, 2025

Download PDF

Apply for Trial

Trial Information

Current as of July 25, 2025

Enrolling by invitation

Keywords

ClinConnect Summary

1. Recent Research Objectives (Within Five Years):

Build a risk prediction model for reproductive women and children in assisted reproduction, and identify potential molecular markers with high predictive value to provide epidemiological evidence clues for further basic mechanism research.

Analyze the health status of natural conception versus assisted reproduction pregnant women and children, growth and developmental curves of fetuses during pregnancy, and early neurobehavioral development levels of children after birth.
2. Medium to Long-Term Research Objectives (Future Research D...

Gender

ALL

Eligibility criteria

Inclusion Criteria:
• (1) Previous or planned IVF treatment; (2) paper or electronic medical records during fertility treatment are available; (3) Obtain informed consent from the research subject or guardian of the minor.
Exclusion Criteria:
• (1) Other assisted reproductive treatment techniques that exclude in vitro fertilization, including guided intercourse, ovulation induction, artificial insemination, etc.; (2) refusal of enrollment; (3) withdraw or abort the study at any time and for any reason.

About Peking University Third Hospital

Peking University Third Hospital is a leading medical institution in China, renowned for its commitment to advanced healthcare, innovative research, and comprehensive clinical services. As a prominent sponsor of clinical trials, the hospital emphasizes the integration of cutting-edge scientific research with patient-centered care to enhance therapeutic outcomes. With a multidisciplinary approach, the institution fosters collaboration among top-tier medical professionals and researchers, striving to contribute to the global medical community through rigorous clinical studies that address pressing health challenges. Its dedication to ethical standards and regulatory compliance ensures the safety and efficacy of new treatments, ultimately aiming to improve patient care and outcomes on both a national and international scale.

Locations

Beijing, Beijing, China

Patients applied

0 patients applied

Trial Officials

Jie Qiao, PhD

Study Chair